Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Medical Department, Division of Hepatology and Gastroenterology, Berlin, Germany.
Asklepios Klinik St. Georg, Department of Internal Medicine and Gastroenterology, Hamburg, Germany.
JPEN J Parenter Enteral Nutr. 2021 Mar;45(3):652-656. doi: 10.1002/jpen.1982. Epub 2020 Aug 21.
The glucagon-like peptide-2 (GLP-2) analogue teduglutide is a medical treatment option for patients with short-bowel syndrome-associated chronic intestinal failure. Because studies in mice have shown that GLP-2 analogues may promote the growth of colonic neoplasms, surveillance colonoscopies before and during teduglutide therapy were recommended. The occurrence of small-intestinal neoplasms has not been reported so far, except for a recent report about de novo development of hamartomatous duodenal polyps. We report a case of de novo development of small-intestinal premalignant adenomatous polyps in both bulbar duodenum and distal jejunum in a patient treated with teduglutide for 41 months. Therefore, additional endoscopic surveillance of the upper gastrointestinal tract may be advised during teduglutide therapy for early detection and removal of potential small-bowel adenomas.
胰高血糖素样肽-2（GLP-2）类似物特迪格鲁肽是治疗短肠综合征相关慢性肠衰竭患者的一种选择。由于在小鼠中的研究表明 GLP-2 类似物可能促进结肠肿瘤的生长，因此建议在特迪格鲁肽治疗前和治疗期间进行结肠镜监测。到目前为止，除了最近关于十二指肠错构瘤新发病变的报道外，尚未报告小肠肿瘤的发生。我们报告了一例在接受特迪格鲁肽治疗 41 个月的患者中，球部和远端空肠均出现小肠前恶性腺瘤性息肉的病例。因此，在特迪格鲁肽治疗期间，可能需要额外对上消化道进行内镜监测，以便早期发现和切除潜在的小肠腺瘤。
